Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)
Conditions
Interventions
Placebo
IBI362
Locations
23
China
Xuancheng People's Hospital
Xuancheng, Anhui, China
People's Hospital of Peking University
Beijing, Beijing Municipality, China
Luoyang Third People's Hospital
Luoyang, He'nan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, He'nan, China
The First Affiliated Hospital of Nanyang Medical University
Nanyang, He'nan, China
The Third Affiliated Hospital of Xinxiang Medical University
Xinxiang, He'nan, China
Start Date
November 14, 2022
Primary Completion Date
August 21, 2023
Completion Date
April 16, 2024
Last Updated
November 12, 2024
NCT07351045
NCT07255209
NCT07128888
NCT06862791
NCT07081958
NCT06867718
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions